OxyContin
(Oxycodone Hydrochloride)Phase 3Small molecule
Oxycodone is a strong painkiller used to treat moderate to severe pain, such as pain from cancer, injury, or surgery. It works by changing how the brain and nervous system respond to pain.[1] OxyContin is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
OxyContin is one of 145 small molecule programs targeting Drug Dependence. It is currently in Phase 3.
5
Indications
26
Total Trials
3
Active Trials
144
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
242 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
OxyContin
PPurdue Pharma LP
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oxycodone9 trials
Show 6 more trials
Cancer Pain2 trials
Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 4·NCT00378937·30 enrolled
Shoulder Arthroplasty2 trials
Single Dose2 trials
10 more indications
Efficacy and Safety1 trial
Abuse Potential1 trial
Head and Neck Cancer1 trial
Post Operative Pain1 trial
Bone Fracture1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxycodone Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Mu Opioid Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPurdue Pharma LP